热门资讯> 正文

早些时候报道，加拉帕戈斯公司在以167.5亿美元收购Ouro后，着眼于与Gilead在T Cell Engager计划上进行战略合作，并额外支付5亿美元里程碑付款

2026-03-24 15:39

Galapagos intends to enter into a strategic collaboration with Gilead following Gilead's acquisition of Ouro Medicines
New partnership structure would achieve meaningfully improved financial terms and flexibility for Galapagos
Following this potential transaction, the Company will continue to have a majority of its capital available for additional strategic transactions and other capital allocation priorities

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。